Browse Articles
Discover research articles across all indexed journals
Autonomic impairment in advanced heart-failure patients revealed by nonlinear heart rate variability measured during exercise
Nationwide randomized, phase III, placebo-controlled trial of bupropion for cancer-related fatigue: Primary outcome results.
LBA12003 Background: Fatigue is common and debilitating among people with cancer. Treatment options for cancer-related fatigue are limited. Methylphenidate demonstrates limited efficacy and low tolerability. Behavioral interventions include exercise and cognitive-behavioral therapy, which many individuals may be unwilling or unable to adopt. Additional therapies are needed. Bupropion has been shown to reduce two hypothesized mechanisms of cancer-related fatigue (CRF), systemic inflammation and hypothalamic pituitary adrenal (HPA) axis functioning. A large-scale, placebo-controlled evaluation of bupropion is needed to offer a potential new therapeutic option for CRF. Methods: The trial was conducted through the University of Rochester Cancer Center National Cancer Institute Community Oncology Research Program (URCC NCORP) Research Base and member sites across the U.S. Eligible patients were adults with any stage or site of disease who reported moderate to severe worst fatigue (i.e., score of 4 or above on 0-10 scale) in past week and had no reported or documented contraindication to bupropion. They completed surgery, radiation, and/or intravenous (IV) anticancer therapy at least two months prior to enrollment. Individuals receiving oral therapies or IV supportive therapy were eligible. Participants were randomized 1:1 to receive over-encapsulated 150 mg bupropion or a placebo. They were instructed to take one capsule in week 1, two capsules in weeks 2-12, and one capsule in week 13. The primary outcome was group differences in the FACIT-F fatigue subscale score at week 12. ANCOVA was conducted with group as the main factor and baseline FACIT-F score as a covariate. Study site was included as a random effect independent of residual error. The study was designed with a statistical power of 90% to identify a difference of 0.30 SD in the FACIT-F score, which corresponds to a clinically meaningful change. Results: Participants (N = 428) had a mean age of 61 years (SD = 12). Most were female (83%), white (86%), non-Hispanic (93%), and/or diagnosed with breast cancer (73%). There were no baseline group differences in demographic, clinical, or fatigue variables ( p values>0.13), except the bupropion group was less likely to have received radiation (65% vs. 74%, p = 0.05). Intent-to-treat analyses indicated that bupropion significantly reduced fatigue (Cohen’s d = 0.23, p = 0.03) relative to placebo. Prespecified moderator analyses indicated that bupropion was associated with significant improvements in fatigue in women (Cohen’s d = 0.33, p = 0.006) but not men ( p = 0.24). Conclusions: In this large, phase III, community-based trial, bupropion resulted in modest reductions in fatigue relative to placebo, particularly among women. Bupropion should be considered in the pharmacologic management of CRF. Clinical trial information: NCT03996265 .
Mechanistic insights into activation of bacterial Retron-Eco8 immunity by phage protein SSB
Green synthesis of cadmium sulfide quantum dots coated with quercus infectoria and Heracleum persicum: cytotoxicity studies on RBCs and HFF-2 cells
Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment
Abstract The exposure and both Mycobacterium tuberculosis clearance rates and toxicity relationships of bedaquiline-pretomanid-linezolid- (BPaL), BPaL-clofazimine (BPaLC) and BPaL-moxifloxacin (BPaLM) for treatment of rifampicin-resistant tuberculosis remain understudied. Therefore, the relationship between the patients’ exposure to anti-TB drugs in TB-PRACTECAL trial investigational regimens and their treatment outcomes was investigated. PRACTECAL-PKPD was a prospective pharmacokinetics and pharmacodynamics study. Patients with rifampicin-resistant tuberculosis were enrolled from Belarus and South Africa. Antimicrobial exposures for bedaquiline, pretomanid, linezolid, moxifloxacin and clofazimine were adequately estimated, were within the ranges of previously published studies but did not correlate with the speed of sputum bacterial clearance. When compared to the standard of care (SoC) arm, a 20% increased bacillary killing rate with BPaLM was observed, whilst BPaL and BPaLC displayed a 15% decreased rate. Also of note was a 20% decreased bacillary killing rate in patients with severe disease irrespective of treatment. Linezolid exposure was higher amongst patients with anaemia or neutropenia. No other exposure-toxicity relationships were identified for all other drugs. These data indicate that the studied doses of linezolid and moxifloxacin could be the right balance between effectiveness and safety, strengthening the WHO recommendation that BPaLM is the preferred regimen for rifampicin-resistant tuberculosis in adolescents and adults. The study was registered in Clinical Trials.gov, TRN: NCT04081077.
Tuning *OH Oxidativity via a Cu–Co(OH) <sub>2</sub> Cocatalyst on a Hematite Photoanode for Selective Cyclohexanone Oxidation
Adaptive filtering method for reducing signal saturation induced artifacts in X-ray dark-field tomography
Abstract X-ray dark-field imaging provides information of an object based on its small-angle scattering properties. Dark-field contrast originates from differences in the strength of scattering from micron and sub-micron sized structures in the object. A Talbot-Lau interferometer can be utilized for dark-field imaging with regular X-ray tubes. A known difficulty with the method arises, when the scattering is too strong, preventing the dark-field and phase retrieval to work accurately. This is similar to a strongly absorbing object in attenuation-based X-ray imaging, and causes problems in tomographic reconstruction that depends on the accuracy of the projected signal. In this article, we present an adaptive filtering approach for the dark-field and phase-contrast projections to improve the signal-to-noise ratio in image areas where the dark-field signal is close to saturation. This filtering improves the projection images markedly, and enables tomographic reconstruction even in cases where the sample contains strong scatterers.
Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy
Bioresorbable electrochemical sensors for continuous deep-tissue lactate monitoring in critical care
A Vibrational Probe of Electrical Doping in N2200 and Fermi-Level Alignment at Polymer Cathode/Metal Cocatalyst/Electrolyte Junctions
Association between the lifelines diet score and the odds of prediabetes and type 2 diabetes mellitus in Iranian adults: a cross-sectional study
Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.
LBA7506 Background: A growing number of patients (pts) entering second-line treatment (tx) are anti-CD38 monoclonal antibody (mAb)- and lenalidomide (LEN)-exposed, limiting tx options. Mezigdomide (Mezi), a potent oral CELMoD, induces maximal, rapid Ikaros/Aiolos degradation leading to enhanced MM cell death and immune stimulation vs IMiDs. We report initial results from SUCCESSOR-2 (NCT05552976), the first randomized phase 3 study of Mezi in RRMM, evaluating MeziKd vs Kd. Methods: In this phase 3, 2-stage, inferentially seamless trial, eligible adult pts had ≥1 prior line of therapy (LOT) including an anti-CD38 mAb and LEN. Pts were randomized 3:3:3:2 (Mezi 0.3, 0.6, 1.0 mg + Kd, or Kd) to identify the optimal Mezi dose in stage 1, and 3:2 to compare efficacy and safety of MeziKd vs Kd in stage 2. MeziKd was given in 28-day (D) cycles of Mezi (D1–21), 56 mg/m 2 carfilzomib (CFZ) weekly (QW), and 40 mg dexamethasone (DEX) QW. The Kd arm received CFZ 56 mg/m 2 twice weekly or 70 mg/m 2 QW + DEX. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, selected Mezi dose (stage 1), overall response rate (ORR), and safety. Results: The Mezi dose selected for stage 2 was 1.0 mg. In total, 479 pts (288 MeziKd at 1.0 mg Mezi; 191 Kd) were included in the analysis. Median (range) age was 68 (30–85) y with 25.1% of pts ≥75 y; median (range) number of prior LOTs was 2 (1–9); 92.1% of pts were triple-class-exposed, with 85.8% refractory to an anti-CD38 mAb and 75.8% to LEN; 37.2% were exposed to pomalidomide and 7.3% to anti-BCMA tx. At data cutoff, median follow-up was 10.6 mo with 52.4% (MeziKd) and 31.4% (Kd) of pts still on tx. Median tx duration was 8.9 (up to 32.1) mo for MeziKd vs 6.2 (up to 25.0) for Kd. MeziKd significantly improved PFS vs Kd (median [95% CI], 18.0 [14.5–22.1] vs 8.3 [5.6–10.7] mo; HR, 0.48 [95% CI, 0.36–0.63]; P <0.0001), which was consistent across subgroups, including pts with >2 prior LOTs, prior tx exposure/refractoriness, high-risk cytogenetics, extramedullary disease, and age ≥75 y. Higher ORR (80.2% vs 53.4%) and complete response or better (26.7% vs 8.9%) were seen with MeziKd. Deaths were reported in 21.5% (MeziKd) vs 26.7% (Kd) of pts, mostly due to progressive disease. Grade (Gr) 3–4 treatment-emergent adverse events were seen in 83.7% vs 56.5% of pts, neutropenia in 61.1% vs 9.1%, and infections in 34.0% vs 15.6% with MeziKd and Kd, respectively; Gr 5 infections in this high-risk population were few (2.4 vs 1.1%). Conclusions: MeziKd showed a clinically meaningful PFS benefit as early as first relapse in predominantly triple-class-exposed, anti-CD38 mAb- and LEN-refractory pts, a population with significant unmet need. These data support Mezi, a potent oral tx with a predictable and manageable safety profile, as a readily accessible, potential new standard of care for RRMM across multiple settings. Clinical trial information: NCT05552976 .
Efficient and durable light-alkane oxidation over sintered Pt catalysts
High-Entropy Alloy Aerogels with High-Density Solid–Solid Heterointerfaces for Alkaline Hydrogen Evolution
A direct interaction of JAM-C with the tight junction scaffold protein ZO-2
Abstract Tight junctions are sites of cell-cell contacts at the apical region of epithelial junctions that are involved in barrier formation, cellular signaling, and cell-cell adhesion. Tight junctions are formed by integral membrane proteins associated with cytoplasmic scaffolding and adapter proteins through which they are linked to the underlying actomyosin and microtubule cytoskeletons. Here, we have addressed the interaction of the Junctional Adhesion Molecule (JAM)-C with the zonula adherens (ZO) protein ZO-2. Using a combination of cell-based recruitment assays and biochemical in vitro experiments, we find that JAM-C and ZO-2 directly interact in a PDZ domain-dependent manner. Notably, the interaction requires PDZ domain 3 as well as the SH3 domain of ZO-2, indicating that ZO-2 forms a functional supramodule to interact with JAM-C. We also found that JAM-C is specifically localized to tight junctions in polarized epithelial cells and that JAM-A suppresses JAM-C mRNA expression in these cells. Our findings have implications for important aspects of tight junction biology, including mechanosensing and liquid–liquid phase separation.
Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.
LBA9503 Background: Uveal melanoma (UM) is the most common ocular cancer in adults with up to 50% of patients developing metastasis with high mortality. No FDA-approved systemic treatments exist for HLA-A*02:01 (HLA-A2) -negative metastatic UM (mUM), and therapies effective in other melanoma subtypes have limited efficacy. Darovasertib (darova) is a first-in-class, oral PKC inhibitor that showed encouraging clinical outcomes in a prior phase 1/2 study in combination with the MET inhibitor crizotinib (crizo). Here we present primary safety & efficacy results from the nested phase 2/3 OptimUM-02 trial of darova+crizo as first-line treatment for HLA-A2 negative-mUM. Methods: OptimUM-02 is an open-label study of HLA-A2 negative first-line mUM patients who were randomized 2:1 to receive darova 300 mg plus crizo 200 mg BID or investigator’s choice (IC) of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine). The primary endpoint for efficacy for phase 2 was progression-free survival (PFS) by RECIST (BICR). Other endpoints included investigator assessed PFS (PFS inv ), objective response rate (ORR), duration of response (DOR), disease control rate (DCR: CR+ PR + SD ≥ 12 weeks), and safety. Overall survival, the phase 3 primary endpoint, will be presented as the data matures. Results: Overall 338 patients received at least one dose of study treatment (safety population), 313 comprised the efficacy population. The median PFS by BICR was 6.9 months for darova+crizo (5.6, 8.3) and 3.1 months for IC (1.8, 4.2); HR: 0.42, p<.0001. Median PFS inv was 6.7 months (5.6, 8.2) and 2.7 months (1.7, 4.1) resp; HR 0.36, p< 0.0001. BICR ORR {37.1% [CR 2.4%; PR 34.8%] vs. 5.8% [CR 0%, PR 5.8%], DCR (73.3% vs 31.1%), DOR (median 6.8 months vs. Non-Evaluable) as well as ORR inv [39.5% vs. 1.9%], DCR inv [74.3% vs. 27.2%] and DOR inv (6.8 months vs. NE) all favored darova+crizo (p-value < 0.0001). Preliminary OS is also trending favorably. The most common treatment emergent adverse events (AEs) for darova+crizo were diarrhea (89.5%), nausea (78.2%), peripheral edema (70.7%), & vomiting (53.6%). In the IC arm, these were nausea (41.4%), diarrhea (36.3%), fatigue (33.3%), AST & ALT elevation (31.1%). AEs led to discontinuation & dose reduction of darova in 3.8% & 23.8% and crizo in 10.9% & 27.2% subjects. In the IC arm, 19.2% discontinued due to AEs. The most common Grade 3 or 4 AEs for darova + crizo were diarrhea (10.9%) & syncope (7.9%) and for IC, AST & ALT increase (8.1%), diarrhea (6.1%) & hepatitis (5.1%). Treatment related serious AEs occurred in 9.2% and 25.3% on darova + crizo and IC respectively. One treatment related fatal AE occurred in each arm. Conclusions: In patients with HLA-A2-negative-mUM treated in the first-line setting, darova+crizo demonstrated a clinically and significantly longer PFS, and improved ORR and DCR compared with the investigator’s choice treatment. AEs were consistent with the previously reported safety profiles in each arm. These results support a potential new therapeutic standard for a disease with limited treatment options and poor prognosis. Clinical trial information: NCT05987332 .